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Background: One of the significant tumor immune escape mechanisms and substantial barrier for successful
immunotherapy is tumor-mediated inhibition of immune response through cell-to-cell or receptor/ligand
interactions. Programmed death receptor-1 (PD-1) interaction with its ligands, PD-L1 and PD-L2, is one of the
important strategies that many tumors employ to escape immune surveillance. Upon PD-Ls binding to PD-1, T cell
receptor (TCR) signaling is dampened, causing inhibition of proliferation, decreased cytokine production, anergy
and/or apoptosis. Thus PD-Ls expression by tumor cells serves as a protective mechanism, leading to suppression of
tumor-infiltrating lymphocytes in the tumor microenvironment. Lm-LLO immunotherapies have been shown to be
therapeutically effective due to their ability to induce potent antigen-specific immune responses. However, it has
been demonstrated that infection with Lm leads to up-regulation of PD-L1 on mouse immune cells that can inhibit
effector T cells through PD-1/PD-L1 pathway.
Methods: Therapeutic and immune efficacy of Listeria-based vaccine (Lm-LLO-E7) in combination with anti-PD-1
antibody was tested in E7 antigen expressing TC-1 mouse tumor model. Tumor growth, survival, as well as
peripheral and tumor-infiltrating immune cell profiles after immunotherapy were assessed.
Results: Here we demonstrate that the combination of an Lm-LLO immunotherapy with anti-PD-1 antibody that
blocks PD-1/PD-L1 interaction, significantly improves immune and therapeutic efficacy of treatment in TC-1 mouse
tumor model. Importantly, we show that in addition to significant reduction of regulatory T cells (Treg) and
myeloid-derived suppressor cells (MDSC) in both spleen and tumor microenvironment that are mediated solely by
the Lm-LLO immunotherapy, the addition of anti-PD-1 antibody to the treatment results in significant increase of
antigen-specific immune responses in periphery and CD8 T cell infiltration into the tumor. As a result, this
combinational treatment leads to significant inhibition of tumor growth and prolonged survival/complete
regression of tumors in treated animals.
We also demonstrate that in vitro infection with Lm results in significant upregulation of surface PD-L1 expression
on human monocyte-derived dendritic cells suggesting the translational capacity of this finding.
Conclusions: Our findings demonstrate that combination of Lm-LLO-based vaccine with blocking of PD-1/PD-L1
interaction is a feasible approach with clinical translation potential that can lead to overall enhancement of the
efficacy of anti-tumor immunotherapy.
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Listeria monocytogenes (Lm) is a Gram-positive faculta-
tive anaerobic intracellular bacterium that has been ex-
tensively studied as a vaccine vector for several diseases.
The unique intracellular life cycle of Lm in an antigen-
presenting cell (APC) allows antigen to be processed
and presented in the context of both MHC I and II mol-
ecules, resulting in strong CD8+ and CD4+ T cell-
mediated immune responses [1]. The listeriolysin-O
(LLO) protein is the major virulence factor of Lm re-
sponsible for the lysis of the phagolysosome vacuole. Re-
cently, LLO has been shown to be PAMP-like molecule
by stimulating production of proinflammatory cytokines
and inducing maturation of antigen-presenting cells [2].
Previously published reports have shown that genetically
fusing an HPV16-E7 to a non-functional truncated form
of LLO enhances the immunogenicity of antigens, as com-
pared to the antigen expressed alone in the same system
[3]. Furthermore, this enhanced immunogenicity corre-
lates with a better therapeutic efficacy against established
tumors [3,4].
One of several mechanisms of tumor-mediated immune
suppression is the expression of co-inhibitory molecules
by tumor. Upon engagement to their ligands these mole-
cules can suppress effector lymphocytes in the periphery
and in the tumor microenvironment [5,6]. The PD-1 is
one of the central signaling molecules that may inhibit
T cell immunity when bound to its ligands (PD-L1 or
PD-L2) by inducing T cell apoptosis and anergy [7]. PD-1
is expressed on the surface of activated lymphocytes and
myeloid cells [8]. PD-L1 is expressed on activated T cells,
B cells, dendritic cells and macrophages, in addition to
a wide range of non-hematopoietic cells [9]. PD-L1 is
upregulated on numerous human tumors, and its expres-
sion has been shown to inversely correlate with survival in
different types of cancer [10-15]. The expression of PD-L2
on various tumor cells was also demonstrated [16,17].
It has been shown that tumor eradication can be en-
hanced by PD-L1/PD-1 blockade [18-23]. Recently we
demonstrated that the combination of PD-1 targeting
with vaccine and low-dose cyclophosphamide signifi-
cantly enhances antigen-specific immune responses, de-
creases tumor burden and increases survival of treated
mice [22,24].
Interestingly, in addition to significant immune and
therapeutic potency of listeria-based immunotherapy [3,4],
it has been demonstrated that infection with listeria lead to
up-regulation of PD-L1 on immune cells [25].
Thus, we hypothesized that combination of Listeria-
based vaccine with blockade of PD-1/PD-L interaction
could improve the overall anti-tumor efficacy of
immunotherapy.
Here we tested the therapeutic efficacy and immune
mechanisms of anti-PD-1 antibody combined with listeriaexpressing LLO and E7 antigen (Lm-LLO-E7) in TC-1
tumor model.
Methods
Animals, cells lines, vaccine and other reagents
Six to eight weeks old female C57BL6 mice were pur-
chased from NCI Frederick and kept under pathogen-free
conditions. Mice were cared for under protocols approved
by the NCI Animal Care and Use Committee. TC-1 cells
that were derived by co-transfection of human papilloma-
virus strain 16 (HPV16) early proteins 6 and 7 (E6 and E7)
and activated ras oncogene to primary C57BL/6 mouse
lung epithelial cells were obtained from ATCC (Manassas,
VA), and cells were grown in RPMI 1640 supplemented
with 10% FBS, penicillin and streptomycin (100 U/ml
each) and L-glutamine (2 mM) at 37°C with 5% CO2. Lis-
teria vaccine vectors with or without human papilloma
virus-16 (HPV-16) E7 (Lm-LLO and Lm-LLO-E7) pro-
vided by Advaxis Inc. were generated as described previ-
ously [3]. Both Lm-LLO and Lm-LLO-E7 were injected
intraperitonealy (i.p.) at 5 × 106 CFU/mouse dose. The anti-
PD-1 monoclonal antibody was obtained from CureTech
(Israel) and was injected intravenously (i.v.) at a dose of
50 μg/mouse. All fluorescently labeled antibodies and ap-
propriate isotype controls used for flow cytometry were
purchased from BD Biosciences (San Jose, CA) or
eBiosciences (San Diego, CA).
Mouse and human dendritic cell isolation, purification
and analysis of PD-L1 expression
Mouse dendritic cells (DC) were isolated and purified
from bone marrow as we described earlier [26]. To obtain
human DC, monocytes were isolated from healthy adult
blood donors (National Institute of Health, Blood bank).
Briefly, peripheral blood mononuclear cells (PBMC) were
isolated from gradient centrifugation using Ficoll-Paque
Plus (Amersham Biosciences) and, after washing, allowed
to adhere to tissue culture plates for 2 h at 37°C. Non-
adherent cells were removed by washing, and the adherent
monocytes were cultured in a plate at 37°C, 5% CO2 in
complete RPMI 1640 consisting of RPMI 1640, 2 mM L-
glutamine, penicillin (100 U/ml), streptomycin (100 ug/ml),
10 mM HEPES, 10% fetal bovine serum, 10 mM nonessen-
tial amino acids, 1 mM sodium pyruvate, and 5 × 10-5 M 2-
mercaptoethanol. Cells were cultured in the presence of
GM-CSF (1000U/ml) and IL-4 (500 U/ml) for 4 days to
become immature DCs. GM-CSF and IL-4 were added
again along with fresh medium on day 3. The DC viabil-
ity in cultures was assessed using the trypan blue
exclusion protocol. Trypan blue-negative cells were
considered alive. After culturing DCs from monocytes
for 4–5 days, DCs were collected and transferred to 6
well plate (1 × 106 cells/ml). Different concentrations of
Lm-LLO or Lm-LLO-E7 were added to DCs culture (0,
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gentamicin (50 ug/ml) to kill listeria, and cultured for
48 hr.
Both mouse and human DCs were stained with appro-
priate fluorescently labeled anti-PD-L1 antibody (PE
anti-mouse PD-L1 and FITC anti-human PD-L1). Isotype-
matched mAbs were used as negative controls. The
stained cells were analyzed using FACSCalibur cytometer
and CellQuest software (BD Biosciences).
Tumor implantation and treatment
The therapeutic experiments aimed to analyze tumor
growth and survival were performed as described earlier
[22,24]. Briefly, mice were implanted with 50,000 TC-1
cells/mouse subcutaneous (s.c.) in the right flank on day 0.
On day 8 (tumor size ~3–4 mm in diameter), animals from
appropriate groups (5 mice per group) were injected i.p.
with Lm-LLO or Lm-LLO-E7 with or without anti-PD-1
Ab i.v. Mice were treated with vaccine and anti-PD-1 Ab
one more time on day 15 after tumor implantation. An-
other group of mice remained non-treated. Tumors were
measured every 3–4 days using digital calipers, and tumor
volume was calculated using the formula V = (W2 × L) /2,
whereby V is volume, L is length (longer diameter) and W
is width (shorter diameter). In these experiments mice
were sacrificed when mice became moribund, tumors were
ulcerated or tumor volume reached 1.5 cm3.
In immunologic experiments same groups of mice
were treated similarly, except mice were sacrificed six
days after the second treatment, on day 21. Spleens and
tumors were isolated and analyzed for antigen-specific
immune responses, CD8 T cells, Tregs and myeloid de-
rived suppressor cells (MDSC).Analysis of antigen-specific cellular immune responses,
Tregs, MDSC in periphery and tumors
ELISPOT was used to detect IFNγ production in E7-
restimulated (10 μg/ml) splenocyte cultures from treated
and control mice, as suggested by the manufacturer (BD
Biosciences, San Jose, CA). A CTL Immunospot Analyzer
(Cellular Technology Ltd., Shaker Heights, OH) was used
to analyze spots. The number of spots from irrelevant
peptide (hgp 10025–33- KVPRNQDWL-Celtek Bioscience,
Nashville, TN) re-stimulated splenocytes were subtracted
from E7-restimulated cultures.
Tumor samples were processed using GentleMACS
Dissociator and the solid tumor homogenization protocol,
as suggested by the manufacturer (Miltenyi Biotec, Auburn,
CA). The number of tumor-infiltrating CD8+, CD4+Foxp3+
(Treg) and CD11b+Gr-1+(MDSC) cells were analyzed
within CD45+ hematopoietic cell population using flow cy-
tometry assay as we described earlier [22,26]. The level of
Treg cells and MDSC was also evaluated in spleens oftumor-bearing treated and control mice using the same
flow cytometry assay.
Statistical analysis
All statistical parameters (average values, SD for PD-L1
expression on DC, tumor volumes, ELISPOT and per-
ipheral and tumor-infiltrating cell analysis) and statistical
significance between groups (for peripheral and tumor-
infiltrating cell analysis) were calculated using GraphPad
Prism Software (San Diego, CA). Statistical significance
between groups was determined by one-way ANOVA
with Tukey’s multiple comparison post-test (P < 0.05 was
considered statistically significant).Results
Infection of murine DC with Lm-LLO and Lm-LLO-E7
upregulates surface PD-L1 expression
It was previously demonstrated that mouse splenocytes in-
fection with Lm results in significant upregulation of PD-
L1 expression on the majority of cells, and that the level of
PD-L1 expression was highest among CD11c+ DC [25].
Considering the importance of DC in priming immune re-
sponse and inhibitory role of PD-1/PD-L1 interaction, we
decided first to analyze the effect of Lm-LLO and Lm-
LLO-E7 on the PD-L1 expression on DC. To avoid the in-
fluence of cell-cell interactions within the mixed cell
population on the accuracy of results, we tested the effect
of different concentrations of Lm-LLO and Lm-LLO-E7
on PD-L1 expression on the surface of purified CD11c+
DCs. As shown in Figure 1, both Lm-LLO and Lm-
LLO-E7 significantly upregulate PD-L1 expression at
108 and 109 CFU/ml doses in a dose dependent manner.
Importantly, there were no differences detected between
Lm-LLO- and Lm-LLO-E7-induced PD-L1 upregulation
on DC at any of the tested doses (Figure 1), indicating that
this effect is antigen-independent.
Anti-PD-1 enhances therapeutic efficacy of Lm-LLO-E7
vaccine
After confirming the effect of Lm-LLO and Lm-LLO-E7
on upregulation of PD-L1 expression on DC, and consid-
ering the inhibitory effect of PD-1/PD-L1 interaction we
hypothesize that combination of PD-1/PD-L1 blockade
with Listeria-based vaccine could improve the anti-tumor
efficacy of immunotherapy. To test this hypothesis we
evaluated the effect of anti-PD-1 Ab and Lm-LLO-E7
combination on tumor growth and survival of mice in
TC-1 tumor model based on E7-expressing lung epithelial
cells. We deliberately used a low dose of Lm-LLO-E7, de-
layed treatment schedule and implanted a high number of
tumor cells in order to minimize the effect of vaccine
alone. Mice were implanted with 50,000 TC-1 cells s.c. on
day 0, and on days 8 and 15 after tumor implantation mice
Figure 1 Lm-LLO and Lm-LLO-E7 infection upregulates PD-L1 expression on mouse DC surface. A. Fold increase of PD-L1 expression on
bone marrow derived mouse DC after treatment with different concentrations of Lm-LLO or Lm-LLO-E7 over non-treated control. B. Representative
histogram from one out of three independent experiments.
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out anti-PD-1 Ab (Figure 2A). Another group of mice
remained non-treated.
While Lm-LLO-E7 vaccine alone resulted in slight inhib-
ition of tumor growth, Lm-LLO-E7/anti-PD-1 combinationFigure 2 Addition of anti-PD-1 Ab to Lm-LLO-E7 enhances therapeuti
individual mice for each treatment measured every 3–4 days. C. The Kaplan
three independent experiments.significantly slowed tumor growth (Figure 2B) and resulted
in prolonged survival and complete tumor regression in
20% of treated mice (Figure 2C).
These experiments reveal that combination of anti-
PD-1 Ab with Lm-LLO-E7 vaccine is a feasible strategyc potency of treatment. A. Treatment schedule. B. Tumor volumes of
-Meier plot depicts overall survival. Similar results were obtained from
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vival even at stringent conditions that were used in
these experiments.Combination of anti-PD-1 Ab and Lm-LLO-E7 significantly
enhances antigen-specific immune responses and CD8 T
cell infiltration into the tumor
To define the immune mechanism and evaluate the
immunologic efficacy of Lm-LLO-E7/anti-PD-1 Ab com-
bination we next assessed the levels of antigen-specific
IFNγ-producing cells in spleens from treated tumor-
bearing mice and tumor-infiltrated CD8 T cells. Mice were
implanted with TC-1 cells and treated as described above
for therapeutic experiments, except, six days after the
second treatment mice were sacrificed and spleens and tu-
mors were harvested. Analysis of E7-specific IFNγ-
producing cells was performed using a standard ELISPOT
assay. As expected, treatment with Lm-LLO-E7 alone in-
duced significant levels of IFNγ-producing E7-specific cells
compared to controls (P < 0.001). Notably, addition of PD-1
/PD-L1 blockade with anti-PD-1 Ab, to Lm-LLO-E7
resulted in further significant increase in antigen specific
immune response when compared to Lm-LLO-E7 alone
(P < 0.01) (Figure 3A).
To further determine the mechanism by which com-
bining Lm-LLO-E7/anti-PD-1 Ab exerts its therapeutic
effect, we tested the influence of treatment on tumor-
infiltrated CD8 T cells. Tumor-infiltrated CD8 T cells
were tested on day 21 post tumor implantation in mice
treated as described above. As expected, Lm-LLO-E7
and Lm-LLO-E7/anti-PD-1 Ab showed a significantFigure 3 Addition of anti-PD-1 Ab to Lm-LLO-E7 enhances antigen-sp
tumor-infiltrated CD8 T cell. C57BL/6 mice (n = 5 per group) were treated
were sacrificed. A. IFNγ production in the presence or absence of E7 peptid
Values represent number of spots from E7-re-stimulated culture minus that
numbers of infiltrated CD45+CD8+ T cells were standardized per 10e6 of to
and ***P < 0.001. Similar results were obtained from two independent expeincrease in tumor-infiltrated CD8 T cells compared to
control groups (P < 0.05 for Lm-LLO-E7 alone and P <
0.001 for Lm-LLO-E7/anti-PD-1 Ab) (Figure 3B). Similar
to peripheral immune response, addition of anti-PD-1 Ab
to Lm-LLO-E7 treatment resulted in significant increase
in CD8 T cell tumor infiltration compared to Lm-LLO-E7
alone (P < 0.05) (Figure 3B).Lm-LLO treatment significantly reduces both splenic and
tumor-infiltrated MDSC and Treg cells regardless of
presence of antigen or anti-PD-1 Ab
Two cell subsets with profound immune response in-
hibitory activity are MDSC and Treg cells. Accordingly,
we analyzed these subsets both in periphery and within
tumor microenvironment to understand the impact
of Lm-LLO-E7/anti-PD-1 Ab combinational treatment.
Spleens and tumors harvested six days after second vac-
cination were assessed for percent (spleen) and actual
numbers (tumors) of MDSC and Treg cells. While the
percent of MDSC in spleens of tumor-free animals is
about 2.5%, in presence of tumor this percent signifi-
cantly increases (~15%) (Figure 4A). Interestingly,
treatment with Lm-LLO, regardless of presence of E7
antigen or anti-PD-1 treatment, significantly decreases
the levels of MDSC in spleens compared to control
animals (P < 0.05) (Figure 4A). Similarly, numbers of
tumor-infiltrated MDSC also were significantly de-
creased after treatment with Lm-LLO, Lm-LLO-E7 and
Lm-LLO-E7/anti-PD-1 Ab treatment (Figure 4B). Im-
portantly, Treg cells in both spleens (Figure 5A) and tu-
mors (Figure 5B) were also slightly but significantlyecific immune responses and increases the level of
as on Figure 2A, except on day 21 after tumor implantation mice
e was analyzed in single-cell suspension obtained from spleens.
from irrelevant antigen re-stimulated culture ± SD. B. The absolute
tal tumor cells and presented as mean values ± SD. *P < 0.05, **P < 0.01
riments.
Figure 4 Lm-LLO treatment decreases the levels of splenic and tumor infiltrating MDSC. A. The percentage of splenic CD11b+Gr-1+ MDSC
from treated and control mice C57BL/6 mice (n = 5). B. The absolute numbers of infiltrated CD45+CD11b+Gr-1+ MDSC standardized per 10e6 of
total tumor cells are presented as mean values ± SD. *P < 0.05. Similar results were obtained from two independent experiments.
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or with E7 or anti-PD-1 Ab.
These data suggest that Lm-LLO is solely responsible
for decrease of MDSC and Tregs in both spleens and tu-
mors of treated mice, and that the addition of antigen or
anti-PD-1 antibody does not affect levels of these cells.Infection of human DC with Lm-LLO also leads to
upreguation of surface PD-L1 expression
After demonstrating the therapeutic efficacy and immune
mechanism by which Lm-LLO-E7/anti-PD-1 Ab combin-
ation exerts anti-tumor effect, we decided to test if Lm-
LLO also affect the levels of PD-L1 expression on human
DC and so as, to understand if our findings could be
translated into the clinic. Monocyte-derived human DC
were isolated from PBMC of healthy volunteers as de-
scribed in Methods section. Human DC were infected
with different concentrations of Lm-LLO and Lm-LLO
-E7. We found that, similar to murine DC, both Lm-LLO
and Lm-LLO-E7 infection leads to significant upregulation
of surface PD-L1 (Figure 6A and B and data not shown).
As for murine DC, the PD-L1 upregulation on human
DC was dose dependent. This finding suggests thatcombination of listeria-based vaccine with anti-PD-1
Ab could be a potent and clinically translatable immu-
notherapeutic approach.
Discussion
The PD-1/PD-L1 engagement has been shown to dampen
TCR signaling, decrease cytokine production by the T
cell, thus, reducing proliferation, anergy and/or apoptosis
[27,28]. Accordingly, PD-L1 expression by tumor cells
serves a protective function that can lead to suppression of
tumor-infiltrating effector lymphocytes thus, allowing tumor
to escape immune surveillance [29-31]. On the other hand,
in disease-free conditions, PD-1/PD-L1 interaction serves as
an important factor in preventing autoimmunity [9,32].
It was previously demonstrated that Listeria-based tu-
mor antigen delivery is a therapeutically potent strategy
capable of inducing robust antigen-specific immune re-
sponses, inhibiting tumor growth and prolonging survival
in pre-clinical mouse tumor models [3,4] and is currently
in clinical trials. A Phase 1 study has been completed with
Lm-LLO-E7 [33] and 4 Phase 2 clinical trials are active or
about to be initiated [34].
Interestingly, despite the promising therapeutic potency
of Listeria-based immunotherapies, it was shown that
Figure 5 Lm-LLO treatment decreases the levels of splenic and tumor infiltrating Treg cells. A. The percentage of CD4+FoxP3+ Treg cells
within CD4+ cell population of splenocytes from experimental and control groups. B. The absolute numbers of infiltrated CD45+CD4+FoxP3+ Treg
cells standardized per 10e6 of total tumor cells are presented as mean values ± SD. *P < 0.05. Similar results were obtained from two
independent experiments.
Figure 6 Lm-LLO infection upregulates PD-L1 expression on monocyte-derived human DC surface. A. Fold increase of PD-L1 expression
on human DC after treatment with different concentrations of Lm-LLO over non-treated control. B. Representative histogram of PD-L1 expression
on human DC treated with different concentrations of Lm-LLO. Similar results were obtained from three independent experiments.
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immune cells [25]. This observation allowed us to
hypothesize, that combination of PD-1/PD-L1 blockade
with Listeria-based immunotherapy will result in even more
potent anti-tumor efficacy of treatment. To test this hypo-
thesis we first confirmed the effect of Listeria infection on
PD-L1 expression on both mouse and human DCs and
then evaluated the immune and therapeutic efficacy of
Lm-LLO-E7 combination with anti-PD-1 Ab in mouse
TC-1 tumor model. To minimize the effect of Listeria
vaccine alone and thus, understand the impact of PD-1/PD-
L1 interaction blockade, we used delayed treatment sche-
dule and low dose of Lm-LLO-E7. We demonstrate that
even at these stringent conditions addition of anti-PD-1 Ab
to Listeria-based treatment results in improvement of
tumor-growth inhibition and prolongation of survival and
significantly stronger antigen-specific immune response
compared to Listeria vaccine alone.
We showed previously that combination of anti-PD-1 Ab
with peptide vaccine requires incorporation of single low
dose of cyclophosphamide (CPM) treatment to decrease
Treg cell numbers, and that potent therapeutic efficacy is
seen only when all three components are combined [22,24].
Interestingly, here we found that while addition of anti-PD
-1 Ab to Lm-LLO-E7 also significantly increases infiltration
of CD8 T cells into the tumor, it does not affect the levels of
neither peripheral nor tumor-infiltrated suppressor cells. In-
stead, surprisingly, Lm-LLO regardless of the presence of
antigen or PD-1/PD-L1 interaction blockade, results in sig-
nificant decrease of Treg cells and MDSC in both spleens
and tumors of treated animals. While we previously demon-
strated that Lm-LLO is able to decrease tumor-infiltrated
Treg cells [34], here we demonstrate for the first time, to
our knowledge, that Lm-LLO treatment results in decrease
of MDSC. Although the mechanisms for both Lm-LLO-in-
duced Treg cells and MDSC decrease are still unknown and
currently under investigation in our laboratories, here we
demonstrate that these events along with PD-1/PD-L1 inter-
action blockade with anti-PD-1 Ab lead to increased
antigen-specific immune responses and thus, result in en-
hancement of overall anti-tumor efficacy of treatment.
Conclusions
Overall, our findings demonstrate that combination of
Lm-LLO-based vaccine with anti-PD-1 Ab leads to in-
creased antigen-specific immune responses and tumor-in-
filtrating CD8 T cell, decrease in suppressor cells (Treg
cells and MDSC) and as a result, leads to significant inhi-
bition of tumor growth and prolonged survival/complete
regression of tumors in treated animals. Thus, we show
that combination of Lm-LLO-based vaccine with blocking
of PD-1/PD-L1 interaction is a feasible and translatable
approach that can lead to overall enhancement of the effi-
cacy of anti-tumor immunotherapy.Abbreviations
PD-1: Programmed death receptor-1; PD-L1/2: Programmed death receptor-1
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